BCP
DGX icon

Blue Chip Partners’s Quest Diagnostics DGX Stock Holding History

Blue Chip Partners’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-681
Closed -$106K – 166
2024
Q3 		$106K Buy
+681
New +$102K 0.01% 188
2024
Q1 		– Sell
-2,683
Closed -$370K – 191
2023
Q4 		$370K Buy
2,683
+15
+0.6% +$1.97K 0.04% 101
2023
Q3 		$325K Buy
2,668
+13
+0.5% +$1.73K 0.04% 109
2023
Q2 		$373K Buy
2,655
+13
+0.5% +$1.79K 0.04% 106
2023
Q1 		$374K Buy
2,642
+36
+1% +$5.15K 0.04% 102
2022
Q4 		$408K Buy
+2,606
New +$374K 0.05% 98
2017
Q1 		– Sell
-1,260
Closed -$116K – 127
2016
Q4 		$116K Sell
1,260
-1,710
-58% -$147K 0.05% 122
2016
Q3 		$251K Buy
2,970
+15
+0.5% +$1.26K 0.11% 99
2016
Q2 		$241K Buy
2,955
+15
+0.5% +$1.14K 0.11% 97
2016
Q1 		$210K Buy
2,940
+17
+0.6% +$1.14K 0.1% 97
2015
Q4 		$208K Buy
2,923
+1,231
+73% +$82.8K 0.11% 98
2015
Q3 		$104K Buy
+1,692
New +$118K 0.07% 115

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Blue Chip Partners's DGX Position: Q4 2024 in Review

Blue Chip Partners sold out of Quest Diagnostics (DGX) in Q4 2024, closing a stake of 681 shares — an estimated $106K sold.

Blue Chip Partners first reported a position in DGX in Q3 2015 and held it in 12 quarters. The position peaked at $408K in Q4 2022. 897 funds tracked by Wall St. Rank hold DGX as of Q4 2024.

  • Blue Chip Partners reported no remaining Quest Diagnostics position as of Q4 2024 after selling out during the quarter.
  • Blue Chip Partners sold 681 Quest Diagnostics shares in Q4 2024, an estimated $106K.
  • Blue Chip Partners first reported a position in Quest Diagnostics in Q3 2015 and held it in 12 quarters.
  • Blue Chip Partners's Quest Diagnostics position peaked at $408K in Q4 2022.
  • 897 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2024.

Based on Blue Chip Partners's 13F filing for Q4 2024, filed 31 Jan 2025.